This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Xuebijing injection (XBJ) and sepsis (septicaemia)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Xuebijing injection (XBJ) and sepsis (septicaemia)

  • an herbal-based intravenous preparation, was licensed in 2004 by the National Medical Products Administration (NMPA, China) for the treatment of sepsis and multiple organ dysfunction syndrome

  • Xuebijing injection (XBJ)
    • possesses an array of activities associated with its mechanism of protection in sepsis
    • can exert an antagonistic effect on endotoxin
    • an inhibitory effect on the uncontrolled release of endogenous inflammatory mediators produced by endotoxin-stimulated monocytes/macrophages
    • can improve the coagulation disorders present in disseminated intravascular coagulation

  • in this randomized clinical trial that included 1817 patients with sepsis, the 28-day mortality rate was 18.8% in the XBJ group vs 26.1% in the placebo group, a significant difference (1):
    • among patients with sepsis, treatment with XBJ, compared with the placebo group, resulted in lower 28-day mortality

Reference:

  • Liu S, Yao C, Xie J, et al. Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial. JAMA Intern Med. Published online May 01, 2023. doi:10.1001/jamainternmed.2023.0780

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.